<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2007-10-21" updated="2020-01-02">
  <drugbank-id primary="true">DB05196</drugbank-id>
  <name>ACR325</name>
  <description>ACR325 is developed for the treatment of Parkinsonâ€™s disease and psychoses, including bipolar disorder, for which disease existing therapies have only limited effect and considerable adverse side effects. ACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor functions and psychoses.</description>
  <cas-number/>
  <unii/>
  <state>solid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Investigated for use/treatment in affective disorders, bipolar disorders, and psychosis.</indication>
  <pharmacodynamics/>
  <mechanism-of-action>ACR325 is a dopaminergic stabiliser. The compound significantly increases the level of dopamine and noradrenalin in the forebrain and concurrently inhibits the over-activity of dopamine in other regions of the brain without unwanted inhibitory effect on motor activity.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms/>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories/>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910017</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>